Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bogart

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
The American Journal of Managed Care|November 21, 2019
Cost analysis of COPD exacerbations and cardiovascular events in SUMMITRichard H Stanford, Anna D Coutinho, Michael Eaddy, et al.
Journal of Asthma and Allergy|December 28, 2020
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe AsthmaJared Silver, Michael Bogart, Elizabeth Packnett, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 2, 2023
Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United StatesJared Silver, Arijita Deb, Elizabeth Packnett, et al.
Respiratory Medicine|September 2, 2018
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective studyMichael Bogart, Richard H Stanford, Tyler Reinsch, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 19, 2022
Impact of mepolizumab in patients with high-burden severe asthma within a managed care populationNjira L Lugogo, Michael Bogart, Thomas Corbridge, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 7, 2023
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VIMichael Bogart, Carl B Abbott, Mohan Bangalore, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 31, 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USANicola A Hanania, Scott H Bunner, Lindsay G S Bengtson, et al.
Clinical Therapeutics|December 11, 2021
Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysisJared Silver, Nestor Molfino, Michael Bogart, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 6, 2021
Factors leading to discontinuation of biologic therapy in patients with severe asthmaJared Silver, Michael Bogart, Nestor A Molfino, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 14, 2019
Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured populationMichael Bogart, Richard H Stanford, François Laliberté, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
The American Journal of Managed Care|November 21, 2019
Cost analysis of COPD exacerbations and cardiovascular events in SUMMITRichard H Stanford, Anna D Coutinho, Michael Eaddy, et al.
Journal of Asthma and Allergy|December 28, 2020
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe AsthmaJared Silver, Michael Bogart, Elizabeth Packnett, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 2, 2023
Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United StatesJared Silver, Arijita Deb, Elizabeth Packnett, et al.
Respiratory Medicine|September 2, 2018
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective studyMichael Bogart, Richard H Stanford, Tyler Reinsch, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 19, 2022
Impact of mepolizumab in patients with high-burden severe asthma within a managed care populationNjira L Lugogo, Michael Bogart, Thomas Corbridge, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 7, 2023
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VIMichael Bogart, Carl B Abbott, Mohan Bangalore, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 31, 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USANicola A Hanania, Scott H Bunner, Lindsay G S Bengtson, et al.
Clinical Therapeutics|December 11, 2021
Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysisJared Silver, Nestor Molfino, Michael Bogart, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 6, 2021
Factors leading to discontinuation of biologic therapy in patients with severe asthmaJared Silver, Michael Bogart, Nestor A Molfino, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 14, 2019
Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured populationMichael Bogart, Richard H Stanford, François Laliberté, et al.
Pageof 4